Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck and Roche have entered into a non-exclusive pact, through their respective subsidiaries, to globally promote Victrelis (boceprevir) in combination with peginterferon alfa and ribavirin (peg/riba).
Subscribe to our email newsletter
As per the terms of the agreement, both the parties will jointly work to educate patients and physicians on hepatitis C virus (HCV) in Europe, Asia and Latin America.
Merck Global Human Health executive vice president and president said reaching physicians with important information about the use of Victrelis in combination with peg/riba is essential as they enter this new era in the field of chronic hepatitis C.
Roche Pharmaceuticals Division chief operating officer Pascal Soriot said through this extended collaboration and the education of health care professionals, Roche and Merck aim to ensure that appropriate patients can benefit from triple combination therapy.
Merck and Roche previously entered into an agreement to promote Victrelis in the US and explore new treatment regimens for chronic HCV.